| Patient | Mildred Ella Didrikson Zaharias |
|---|---|
| Date of birth | 1911-06-26 |
| Identifiers | MRN HR-ML038-SYN-TD; SSN (made up) 000-38-4471 |
| Document date | 1953-08-10 |
| Author | Rosalind Vasquez-Thornbury, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Periodic adult preventive visit, on the day of cycle 7 of dostarlimab. [S]
Ms. Didrikson Zaharias, now 42, comes for her yearly preventive visit on the morning of her seventh dose of dostarlimab. Six weeks ago, at the restaging visit, the tumor had almost gone on MRI and endoscopy, and levothyroxine 75 micrograms was started for immune-related hypothyroidism. She takes it on waking, four hours apart from her iron, and the tiredness and cold hands have gone. Her bowel movements are normal, with no blood, urgency or pain. She is playing 18 holes most days and finished third in a regional event last week. She has had no diarrhea, rash, cough or breathlessness since the cold in June. Her PHQ-9 today is 2. [S]
| Element | Detail |
|---|---|
| Visit | Periodic adult preventive visit, age 42 |
| Active conditions | Mismatch repair-deficient low rectal cancer on dostarlimab with a near-complete response; immune-related hypothyroidism on levothyroxine; iron deficiency anemia, recovering |
| Medicines | Dostarlimab every three weeks; levothyroxine 75 micrograms daily; ferrous sulfate 325 mg on alternate days; levonorgestrel intrauterine device |
| Mood | PHQ-9 2 |
Health risk assessment. Completed by the patient on a tablet in the waiting room and reviewed with her by Dr. Vasquez-Thornbury. [S]
| Domain | Finding |
|---|---|
| Self-rated health | Very good |
| Psychosocial | Busy with tournaments and the club; worried at times that the cancer will come back; sleeps well |
| Tobacco | Never smoked |
| Alcohol and drugs | A drink once or twice a month; no drugs |
| Physical activity | Golf most days, walking the course; strength work three times a week |
| Nutrition | Has cut red meat to twice a week and eats more vegetables and whole grains |
| Sun exposure | Outdoors most of the day; uses sunscreen inconsistently; wears a visor |
| Sexual and reproductive health | Sex comfortable again since the bleeding stopped; levonorgestrel IUD in place; not planning a pregnancy |
| Safety at home | Feels safe; no one hurts, threatens or controls her; no firearm in the home |
| Road safety | Wears a seat belt; drives long distances between tournaments and stops to rest |
| Activities of daily living | Independent |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever, night sweats or weight loss; energy back to normal |
| Eyes | Negative | No vision change; eye examination last year |
| Ears, nose, mouth, and throat | Negative | No mouth sores |
| Cardiovascular | Negative | No chest pain or palpitations |
| Respiratory | Negative | No cough or breathlessness |
| Gastrointestinal | Negative | Normal bowel movements; no blood, urgency or pain |
| Genitourinary | Negative | Light periods with the IUD; no urinary symptoms |
| Breast | Negative | No lump or nipple discharge |
| Musculoskeletal | Negative | No joint pain or swelling |
| Integumentary | Negative | No rash or itching; no changing moles |
| Neurological | Negative | No headache or numbness |
| Endocrine | Negative | Cold intolerance gone; no thirst |
| Psychiatric | Negative | Mood good; PHQ-9 2; no thoughts of self-harm |
13 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Ferrous sulfate 325 mg (65 mg elemental iron) oral tablet, one tablet by mouth every other morning | One tablet every other morning | Oral route | 1953-03-30 | active | S |
| Dostarlimab-gxly 50 mg/mL injection, 500 mg intravenously over 30 minutes every 3 weeks, for nine doses (six months) | 500 mg every 3 weeks for nine doses | Intravenous route | 1953-04-06 to 1953-09-21 | completed | S |
| Levothyroxine 75 microgram oral tablet, one tablet by mouth each morning on an empty stomach, four hours apart from iron | One tablet each morning | Oral route | 1953-06-29 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1953-08-10 | Body height | 168 | cm | S |
| 1953-08-10 | Body weight | 63.6 | kg | S |
| 1953-08-10 | Body mass index (BMI) [Ratio] | 22.5 | kg/m2 | S |
| 1953-08-10 | Systolic blood pressure | 112 | mm[Hg] | S |
| 1953-08-10 | Diastolic blood pressure | 68 | mm[Hg] | S |
| 1953-08-10 | Heart rate | 62 | /min | S |
| 1953-08-10 | Respiratory rate | 14 | /min | S |
| 1953-08-10 | Body temperature | 36.5 | Cel | S |
| 1953-08-10 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1953-08-10 | Thyrotropin [Units/volume] in Serum or Plasma | 3.1 | m[IU]/L | 0.45-4.5 mIU/L | Normal | S |
| 1953-08-10 | Thyroxine (T4) free [Mass/volume] in Serum or Plasma | 1.1 | ng/dL | 0.8-1.8 ng/dL | Normal | S |
| 1953-08-10 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 2 | {score} | S |
Vital signs recorded on 1953-08-10; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| Constitutional | Fit and well; weight 63.6 kg, BMI 22.5; blood pressure 112/68 |
| Head, eyes, ears, nose, and throat | Normal |
| Neck | Thyroid not enlarged or tender; no lymph nodes |
| Breasts | Examined with her agreement and a chaperone: no mass, skin change or nipple discharge; no axillary nodes |
| Cardiovascular | Regular rhythm; no murmur |
| Respiratory | Clear to auscultation bilaterally |
| Abdomen | Soft, non-tender; no liver enlargement or mass |
| Skin | Sun-damaged skin on the forearms, face and neck; several solar lentigines; no lesion suspicious for melanoma or other skin cancer |
| Musculoskeletal | Full range of movement of the spine, shoulders and hips |
| Psychiatric | Cheerful, quick and engaged |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Bright red blood with bowel movements for about three months, with narrower stools, urgency, a feeling of incomplete emptying, and a firm, ulcerated mass felt on the back wall of the lower rectum at about 5 cm from the anal verge: a rectal cancer must be confirmed or excluded. Colonoscopy with biopsy booked this week | resolved | confirmed | K62.5 | S — Synthetic presenting problem anchored to the documented fatigue before her cancer diagnosis. Superseded by the diagnosis at the second visit. |
| Iron deficiency anemia from chronic rectal blood loss: hemoglobin 11.0 g/dL, MCV 77 fL, ferritin 9 ng/mL, with tiredness | active | confirmed | D50.0 | S — Synthetic finding anchored to the documented fatigue at the end of the 1952 season. |
| Adenocarcinoma of the low rectum, mismatch repair deficient (loss of MSH2 and MSH6; microsatellite instability high), cT3bN1M0 (stage IIIB) on pelvic MRI, lower edge 4 cm from the anal verge and about 1 cm above the anorectal junction, mesorectal fascia clear, no extramural venous invasion; CEA 5.8 ng/mL; synthetic modern detail linked to her documented cancer, whose site the sources do not record exactly | active | confirmed | C20 | S — Synthetic histology, site, stage, mismatch repair status and course; the sources say she had cancer treated with a colostomy and call it colon cancer (R on the site). See sources.md. |
| Acute viral upper respiratory infection with cough and sore throat, a week before cycle 4 of dostarlimab; oxygen saturation and chest X-ray normal, so immune-related pneumonitis is unlikely; rapid influenza and COVID-19 tests negative; resolved | resolved | confirmed | J06.9 | S — Synthetic intercurrent illness; not a historical claim. |
| Immune-related primary hypothyroidism from dostarlimab, grade 2: tiredness and cold hands, TSH 12.6 mIU/L and free T4 0.6 ng/dL after four doses, following a mild TSH rise four weeks earlier; dostarlimab continued | active | confirmed | E03.2 | S — Synthetic common immune-related adverse event of PD-1 blockade. |
Personalized prevention plan. A written copy was given to the patient. [S]
| Service | Status | Detail |
|---|---|---|
| Blood pressure screening | Completed today | 112/68 mmHg |
| Depression screening | Completed today | PHQ-9 score 2; item 9 scored 0 |
| Unhealthy alcohol use screening | Completed today | One or two drinks a month |
| Tobacco use | Completed today | Never smoked |
| Intimate partner violence screening | Completed today | Negative; she feels safe |
| Breast cancer screening | Ordered | Mammogram every two years from 40; first screening mammogram ordered |
| Cervical cancer screening | Up to date | HPV and cytology co-test two years ago, normal; next in three years |
| Colorectal cancer screening | Not indicated | Screening does not apply: she is under cancer surveillance with MRI, endoscopy and colonoscopy |
| HIV, hepatitis B and hepatitis C screening | Up to date | All negative before treatment; hepatitis B surface antibody negative |
| Prediabetes and diabetes screening | Not indicated | BMI 22.5 with no other risk factor; fasting glucose normal before each cycle |
| Lipid screening | Up to date | Lipid panel three years ago normal |
| Skin cancer prevention counseling | Completed today | Sun protection for an outdoor athlete; skin examined, no suspicious lesion |
| Hepatitis B vaccine | Completed today | Dose 1 of the two-dose adjuvanted series; dose 2 in one month or later |
| Influenza vaccine | Due | When this season's vaccine is available |
| COVID-19 vaccine | Due | This season's vaccine in the autumn |
| Tetanus, diphtheria, and pertussis | Up to date | Tdap five years ago |
| Recombinant zoster vaccine | Not indicated | Recommended from 50, or from 19 for immunosuppression; PD-1 blockade alone is not immunosuppressive treatment |
| Contraception counseling | Completed today | Levonorgestrel IUD continued during treatment and for at least four months after the last dose |
| Dental and vision examination | Due | Dental cleaning due; eye examination next year |
Immunizations given today: Hepatitis B vaccine (adjuvanted, two-dose series), dose 1 [S]
Guideline basis: Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol 2021;39(36):4073-4126 (PMID 34724392) (2021); Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026); USPSTF A and B Recommendations (2026); Breast Cancer: Screening (2024); Cervical Cancer: Screening (2018); Adult Immunization Schedule by Medical Condition and Other Indication (2026)
Follow-up: Cycle 7 today; cycles 8 and 9 as booked; hepatitis B dose 2 at cycle 9; mammogram; final restaging after cycle 9. Next preventive visit in one year. Next scheduled visit 1953-10-05: after nine doses: final restaging, clinical complete response, and the watch-and-wait surveillance plan. [S]
Voluntary advance care planning discussion of about 20 minutes, with her consent. She named a health care agent, recorded in the confidential part of the chart and not named here, and completed a health care proxy form. She said that she wants every treatment with a real chance of controlling the cancer, including surgery and a colostomy if the tumor ever regrows, and wants to be told the facts at once and in plain words. If she were ever too ill to decide and unlikely to recover, she would want care aimed at comfort, with her pain fully treated. To be revisited at each change in her health and at least yearly. [S]